We have examined the influence of plasma protein binding on inter-individual and intraindividual variability in the effective postoperative analgesic concentration (EAC) of alfentanil and on the performance of the target-controlled infusion system used. Ten patients received standardized anaesthesia and target-controlled alfentanil for postoperative analgesia. Analgesia was assessed using a visual analogue scale (VAS). Plasma protein binding of alfentanil was assessed at four different times (on arrival in the recovery room, at 21:00 on the day of surgery and at 09:00 and 21:00 on the first postoperative day). Bias and inaccuracy were examined on the day of surgery and on the first postoperative day. Unbound fractions of alfentanil varied from 5 to 15% and varied in time. In general, the unbound fractions on the day of surgery were higher than those on the first postoperative day. Thirty-nine percent of inter-individual variability in the EAC of alfentanil (range 33-140 ng ml -1 ) at the onset of therapy could be explained by protein binding. At the other observation times, correlations between unbound fraction and EAC were only moderate. Bias on the day of surgery was -19% and 12% on the first postoperative day (ns). Inaccuracy was 23% and 18%, respectively (ns). We conclude that inter-individual variations in plasma protein binding can explain a significant portion of inter-individual variability in the EAC of alfentanil in the early postoperative phase. 1999; 82: 580-5 
Studies using i.v. infusions of alfentanil for postoperative pain relief have demonstrated large inter-individual variability in effective analgesic concentrations (EAC). [1] [2] [3] [4] [5] In addition, EAC values have been shown to vary with time within individuals after surgery. 1 4 Factors that contribute to these observations include variability in the intensity and duration of postoperative pain, inter-and intra-individual variability in pain perception and intraoperative anaesthetic regimen. Another factor that may contribute to both interand intra-individual variability in effective analgesic concentrations is variability in the degree of plasma protein binding. This may be particularly important when protein binding is high (Ͼ90%) as is the case for alfentanil. With alfentanil, small variations in plasma protein binding may cause profound variations in the total plasma concentrationeffect relationships, even when unbound plasma concentration-effect relationships are identical.
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Apart from affecting the plasma concentration-effect relationship (i.e. pharmacodynamics), protein binding may also affect the pharmacokinetics of a drug. This would be expected to be the case with alfentanil, which has a relatively small hepatic extraction ratio (Eϭ0. 4) 6 so that clearance is likely to depend on protein binding.
In this study, we have examined the role of plasma protein binding in inter-individual and intra-individual variability in the EAC of alfentanil and in the performance of the targetcontrolled infusion system used.
Patients and methods
The study was approved by the Medical Ethics Committee of Leiden University Medical Centre. After obtaining informed consent, we studied 10 patients (five males), ASA I or II, aged 18-65 yr, undergoing orthopaedic surgery under general anaesthesia lasting longer than 1 h. Patients with a history of cardiovascular, pulmonary, hepatic or renal disease or rheumatoid arthritis, and those who had received opioids in the preceding month were excluded. Patients received a target-controlled infusion of alfentanil for postoperative pain management. Before surgery each patient was instructed on the use of the system and on the use of the visual analogue scale (VAS, 0-10 cm) for pain scoring.
The anaesthetic technique was standardized. Premedication comprised temazepam 0.3 mg kg -1 orally to the nearest 10 mg, 1 h before surgery. On arrival in the operating room, monitoring equipment was attached and a venous cannula for drug administration established. Subsequently, pancuronium 0.02 mg kg -1 was given and anaesthesia was induced by target-controlled infusion of alfentanil (target concentration: C T ϭ150 ng ml -1 ) and etomidate 0.15-0.3 mg kg -1 . When consciousness was lost, succinylcholine 1 mg kg -1 was given to facilitate intubation of the trachea. After induction of anaesthesia, a 20-gauge cannula was introduced into a radial artery for arterial pressure monitoring and collection of blood samples. Anaesthesia was maintained with 0-1.2% enflurane and 66% nitrous oxide in oxygen, and targetcontrolled infusion of alfentanil (C T ϭ150 ng ml -1 ). Pancuronium was given for neuromuscular block. When signs of inadequate anaesthesia developed, enflurane concentration was increased to a maximum end-tidal concentration of 1.2%. If anaesthesia was still inadequate, the C T of alfentanil was increased in steps of 20-50 ng ml -1 . After surgery, droperidol 1 mg i.v. was given to prevent nausea and vomiting. Supplementary oxygen was given routinely on arrival in the recovery room and discontinued before discharge from the recovery room.
After operation, patients were instructed to report the onset of pain to one of the investigators. The targetcontrolled infusion was restarted with a C T equal to the plasma concentration of alfentanil predicted by the computer (C PRED ) at that moment when C PRED was Ͼ50 ng ml -1 . If C PRED was ഛ50 ng ml -1 , the target-controlled infusion was restarted with C T ϭ50 ng ml -1 . During the loading period, VAS scores and degree of sedation using the six-point scale described by Ramsay and colleagues 7 were assessed every 10 min. If the patient indicated a need for additional analgesia, C T was increased by 10 ng ml -1 . C T was not altered when the patient indicated no need for additional analgesia. The loading period was ended when C T had not been changed for 30 min. Thereafter, the patient was given a button, which, when pushed, alerted the investigator controlling the target-controlled system and the step size in C T was decreased to 5 ng ml -1 with a lockout time of 10 min. When C T had not changed for 2 h, C T was decreased by 5 ng ml -1 every 15 min until a request for additional analgesia was made, when C T was increased by 5 ng ml -1 , as described above.
Every 10 min during the first hour of the study, every hour during the remaining observation period (until 21:00 on the first postoperative day) and before and 10 min after 581 a demand for additional analgesia, the VAS score, sedation score and vital signs were documented. No VAS scores were obtained when the patient was asleep. Peripheral oxygen saturation (Sp O 2 ) (Nellcor, Hayward, Ca, USA) and heart rate were recorded continuously and a respiration monitor (MR10, Graseby Medical, Watford, UK) recorded ventilatory frequency. When ventilatory frequency was Ͻ8 bpm and/or Sp O 2 was Ͻ90%, arterial blood-gas analysis was performed to confirm respiratory depression (Sa O 2 Ͻ90% and/or arterial Pa CO 2 Ͼ7.3 kPa.). Side effects observed during the postoperative period were noted.
On arrival in the recovery room, at 21:00 on the day of surgery and at 09:00 and 21:00 on the first postoperative day, a 10-ml arterial blood sample was obtained for measurement of total plasma concentration and degree of plasma protein binding of alfentanil. Additional arterial blood samples (3 ml) for measurement of total plasma concentrations of alfentanil were collected before every increase in C T of alfentanil. A blood sample was also collected 10 min after a new C T was achieved, provided the patient did not require additional analgesia at that time. The maximum amount of blood collected was restricted to 250 ml per patient.
Plasma was obtained by centrifugation and stored at -20°C until analysis. Plasma protein binding of alfentanil was determined in duplicate by equilibrium dialysis with a Dianorm dialysis system, equipped with 20 Teflon dialysis cells (Diachema, Rüschlikon, Switzerland). 8 The cell membranes had a molecular weight cut-off of 10 000 Da. Alfentanil was added to 1 ml of plasma samples to obtain final concentrations of approximately 300-400 ng ml -1. Subsequently, the samples were dialysed against 2 ml of an isotonic phosphate buffer solution. The dialysis was carried out in a thermostat water bath at 37°C for 4 h at 20 rpm. Under these conditions binding of alfentanil to the membrane or cell walls was minimal (Ͻ5%). 8 Free fractions (F u ) of alfentanil were measured from the concentrations C MEAS of alfentanil in plasma before dialysis and the concentration C D in dialysate after dialysis using the equation:
where R is the ratio of the volumes of the buffer solution and plasma before dialysis (Rϭ2). A capillary gas chromatographic technique 9 was used to determine plasma and dialysate concentrations of alfentanil. The detection limit was 0.1 ng ml -1 . The coefficient of variation in the concentration range (Ͼ1 ng ml -1 ) encountered in this study was Ͻ5%.
Data analysis
The performance of the target-controlled infusion system, implemented with the population pharmacokinetic data from Maitre and colleagues, 10 was assessed by examining bias and inaccuracy, as described by Raemer and colleagues. 11 For each blood sample, the performance error (PE) was calculated as
where C MEAS is the measured plasma concentration of alfentanil and C PRED the corresponding predicted plasma concentration. The bias of the system was expressed as median PE (MDPE) for all blood samples included. The system inaccuracy is the median of the absolute values of the individual PE (MDAPE). MDPE and MDAPE were calculated for each patient from all blood samples collected from that patient. In addition, MDPE and MDAPE for individual patients were calculated from all blood samples collected on the day of surgery from the end of surgery until 0:00, from all blood samples collected on the first postoperative day and from all samples collected during the entire study. Data points with C MEAS Ͻ5 ng ml -1 and C T ϭ0 ng ml -1 were omitted from analysis.
Data are presented as mean (SD) or median (95% confidence interval (CI) or range), as appropriate. The relationship between unbound fractions (F u ) and the effective analgesic concentration (EAC) at the four assessment times was examined using linear regression and correlation analysis. The effective analgesic concentration was defined as the measured plasma concentration of alfentanil at which the patient indicated no need for additional analgesia, and had a VAS score ഛ3.0. For each patient, the total time and time intervals with pain scores Ͼ3.0 were calculated. The effect of time on F u was examined with repeated measures analysis of variance, followed by Newman-Keuls tests. MDPE and MDAPE on the day of surgery and on the first postoperative day were compared using the Wilcoxon paired sample test. PϽ0.05 was regarded as the minimum level of statistical significance. For analysis, Quattro Pro for Windows (Borland International Inc, Scotts Valey, USA) and InStat (USA) were used.
Results
Patient data, duration of anaesthesia, intraoperative alfentanil consumption and characteristics of the time course of pain treatment are presented in Table 1 . Median duration of the study from arrival in the recovery room until 21:00 on the first postoperative day was 30 (range 28-32) h. The treatment was fast in onset and effective. There were no unrewarded demands. The median number of hourly observations with VAS scores ഛ3.0 was 18 (range 11-28); with VAS scores Ͼ3.0 it was 4 (range 0-13); and with the patients asleep, 7.5 (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Sedation scores at all other observation times were ഛ3. EAC values are presented in Table 2 and showed marked inter-individual and intra-individual variability; several patients did not require alfentanil at the last observation time. Linear regression analysis demonstrated a strong correlation between F u and EAC in the early postoperative phase (Fig. 1) , with F u , explaining 39% of the interindividual variability in EAC. A moderate correlation between F u and EAC was also observed at the second observation time (21:00 on the day of surgery) with F u explaining 25% of the inter-individual variability in EAC. However, much of this can be attributed to the observation in a single patient, in whom a low EAC was associated with a high F u . Correlations between the variables at the study times during the first postoperative day were not significant. Unbound fractions of alfentanil vs time are presented in Figure 2 . Mean unbound fractions were 8.3 (SD 2.2)% at the onset of pain, 9.7 (2.3)% at 21:00 on the day of surgery, 8.0 (2.5)% at 09:00 on the first postoperative day and 7.1 (2.1)% at 21:00. Statistical analysis of these data demonstrated a significant effect of time, but unbound fractions at the third observation time did not differ from those at the first and fourth observation times. The time dependence of F u could not explain the intra-individual variability in EAC. If protein binding is a major factor in this respect, higher EAC values on the first postoperative day would be predicted compared with the day of surgery because F u decreases. However, EAC values on the first postoperative day were generally lower than those on the day of surgery.
Median performance errors in individual patients are presented in Table 3 . Bias calculated from the median performance errors of the 10 individual patients was -19% (95% CI -32% to 26%) on the day of surgery and 12% (95% CI -37% to 21%) on the first postoperative day. Although bias was smaller on the first postoperative day than on the day of surgery, the difference was not significant. Inaccuracy calculated from the median performance errors of the 10 individual patients was 23% (95% CI 19-32%) on the day of surgery and 18% (95% CI 14-37%) on the first postoperative day. Overall, the bias of the system calculated from all blood samples (nϭ295) was -9% and the inaccuracy of the system was 23%.
Ventilatory frequency and postoperative Sp O 2 were always within the clinically acceptable ranges. Sedation score was ഛ3 in all patients at all times when they were not asleep. No patient developed hypotension, defined as a decrease in arterial pressure of more than 15% from preoperative control values. Seven patients needed an additional antiemetic for nausea and vomiting. Urinary retention occurred in five patients, one of whom required a bladder catheter. Pruritus did not occur in any patient.
Discussion
It is believed commonly, but rather difficult to prove, that pharmacological effects are generally more closely related to unbound than to total plasma concentrations. Consequently, variations in plasma protein binding may cause significant There was a significant effect of time on F u (PϽ 0.0001): F u at onset of pain ϽF u at 21.00 on the day of surgery (PϽ0.01); F u at 09:00 on the first postoperative day (PoD1) ϽF u at 21:00 on the day of surgery (PϽ0.01); F u at 21:00 on the first postoperative day ϽF u at onset of pain (PϽ0.05); F u at 21:00 on the first postoperative day ϽF u at 21:00 on the day of surgery (PϽ0.001); F u at onset of pain vs F u at 09:00 on the first postoperative day (ns); and F u at 09:00 on the first postoperative day vs F u at 21:00 on the first postoperative day (ns).
variations in the total plasma concentrations associated with a given effect, even when unbound concentrations associated with that effect are similar. For example, suppose two patients have an EAC of 4 ng ml -1 (unbound concentration) for alfentanil. Let the degree of protein binding in these patient be 92% and 96%, respectively. The corresponding EAC values based on total plasma concentrations would then be 50 and 100 ng ml -1 , a two-fold difference with only 4% difference in the degree of protein binding. In practice, unbound fractions may vary considerably more. In a study 8 examining the influence of protein binding on intraoperative alfentanil requirements, the unbound fraction of alfentanil ranged from 3.7% to 19.1%. Similarly, unbound fractions in our study were 5.0-15.3%. The former study demonstrated that variations in the degree of protein binding explained 40% of the intra-individual variability in the concentrations of alfentanil that were associated with a 50% probability of suppression of responses to surgical stimulation. Similarly, variation in the degree of protein binding explained 39% of the inter-individual variability in the MEAC during the early postoperative phase in this study. However, at later times the correlation between unbound fractions and EAC values were uncertain or nonexistent. A factor that could play a role in this respect is that whereas EAC values during the early postoperative phase were obtained by careful titration, the EAC values at later times were set equal to the plasma concentration at the observation times. Theoretically, these concentrations could slightly overestimate the true EAC values at these times, because plasma concentrations were adjusted downwards at 2-h intervals. However, inspection of the target plasma concentration profiles, patient requests for additional analgesia and VAS scores indicated that plasma concentrations at all observation times were equal or close to the true EAC values. The lack of correlation between the unbound fractions and EAC values at the observation times beyond the early postoperative phase therefore indicates that inter-individual variations at these times are more dependent on other factors, such as pain intensity, possible development of acute tolerance and down-regulation at the receptor level. This holds in particular during the first postoperative day, when EAC values decreased markedly in several patients. Variations in the degree of protein binding may also result in intra-individual variability in the pharmacodynamics of drugs. This holds in particular for drugs that are mainly bound to α 1 -acid glycoprotein (AAG), such as alfentanil. Plasma concentrations of AAG, an acute phase protein, increase gradually in the postoperative phase in response to surgical trauma [12] [13] [14] [15] and a diurnal variation in AAG concentrations in volunteers is reported. 16 This could explain the observed time-dependence in the degree of plasma protein binding, which was increased on the first postopera-584 tive day compared with the day of surgery. However, changes in the degree of protein binding with time were small compared with the changes in EAC and therefore cannot explain the intra-individual variability in EAC. Again, the main source of this variability must be sought in other variables that vary in time, such as intensity of pain.
Changes in plasma protein binding can affect not only the pharmacodynamics of drugs but also their pharmacokinetics. This would be expected with alfentanil. As the hepatic extraction ratio of alfentanil is relatively small (Eϭ0.4), 6 its hepatic clearance is likely to depend on the degree of protein binding. Consequently, with a given target concentration, one would predict somewhat higher plasma concentrations during the first postoperative day compared with the day of surgery. Our study design did not allow a full pharmacokinetic evaluation. None the less, the finding that measured plasma concentrations were, overall, lower than predicted concentrations on the day of surgery and higher on the first postoperative day, probably reflects a change in the pharmacokinetics, secondary to the observed changes in protein binding.
Our study confirmed that target-controlled infusion of alfentanil can provide adequate postoperative pain relief, as has been demonstrated in previous studies. 4 17 The observed bias and inaccuracy indicate that the implemented pharmacokinetic data set is suitable for target-controlled infusion of alfentanil in the postoperative phase. A drawback of the method is that it is associated with a high incidence of side effects, in particular nausea, vomiting and urinary retention.
In summary, this study demonstrated that inter-individual variations in the degree of plasma protein binding can explain a significant portion of the inter-individual variability in alfentanil requirements during the early postoperative phase. However, at later stages plasma protein binding plays a minor role in this respect. Although the degree of plasma protein binding varied with the time after surgery, the variability could not explain the time-dependence in alfentanil requirements. The variability of the performance of the system in time suggests that the pharmacokinetics of alfentanil may change with time.
